Open AccessCisplatin and Nano-particle Formulations of Cisplatin for Cancer Therapy: A Review
Author(s) -
Popsy Raj,
Bharat Lal,
Manoj Gadewar,
Anita Singh,
G. K. Prashanth
Publication year - 2022
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2022/v34i14a35636
Subject(s) - cisplatin , nanocarriers , drug , pharmacology , cancer therapy , drug delivery , anticancer drug , broad spectrum , medicine , nanotechnology , cancer , chemistry , chemotherapy , combinatorial chemistry , materials science
Cisplatin (cis-(diammine)dichloridoplatinum(II)) is the first platinum-based compound approved by the United States Food and Drug Administration (FDA) (U.S.). This is a first-line chemotherapeutic treatment used alone or combined with other anticancer drugs to treat a broad spectrum of malignancies, with cisplatin-based nano-formulations currently in clinical studies. Cisplatin has several drawbacks, including low aqueous solubility, drug resistance, and toxicity, all of which can be addressed by encapsulating the drug in Nemours nanocarriers. The various nano-delivery technologies developed for Cisplatin are covered in vast literature from different electronic databases. This review focuses on comparative findings over the recent advancements, developments, innovations, and updated literature for various CDDP nano-carrier systems.